Bioequivalence evaluation of two brands of cefaclor 500 mg capsules: quantification of cefaclor using solid phase extraction technique

Authors: Tutunji, M.1; Jarrar, O.1; Musameh, M.1; Alam, S. M.2; Dham, R.2

Source: Journal of Clinical Pharmacy & Therapeutics, Volume 26, Number 2, April 2001 , pp. 149-153(5)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: To assess the bioequivalence of two cefaclor 500 mg capsule formulations, and to develop a new high performance liquid chromatographic (HPLC) method using solid phase extraction technique for the quantification of cefaclor in human plasma.

Method: An open, randomized, two-way, crossover trial with a one-week washout period in 25 healthy volunteers. The two commercial brands used were Recocef® (Julphar, United Arab Emirates) as test and Ceclor® (Eli Lilly, UK) as reference product. The drug was administered with 240 mL of water after a 10-h overnight fast. After dosing, serial blood samples were collected for a period of 8 h. Plasma harvested from blood was analysed for cefaclor by a new HPLC method using a solid phase extraction technique. The limit of detection of cefaclor was 17·6 ng/mL; average recovery was 96·5%; the intraday CV was less than 8% and interday CV was less than 13%. Various pharmacokinetic parameters, including AUC0-t, AUC0-∞, Cmax, Tmax, T1/2, and Kel, were determined from plasma concentrations for both formulations. Statistical analysis (ANOVAand 90% confidence intervals) were applied to AUC0-t, AUC0-∞ and Cmax for bioequivalence evaluation of two brands. The new HPLC method with solid phase extraction circumvented the problem of mixed polarity of cefaclor and facilitated its extraction from the complex plasma matrix while keeping the background free from interference due to endogenous plasma compounds.

Results: No significant difference was observed between the two brands of cefaclor capsules.

Conclusion: Recocef® was judged bioequivalent to Ceclor,® and the two products can therefore be considered to be interchangeable in medical practice.

Keywords: bioequivalence; cefaclor; HPLC; pharmakokinetics

Document Type: Research article

DOI: 10.1046/j.1365-2710.2001.00337.x

Affiliations: 1: Pharmaceutical Research Unit (PRU), Amman, Jordan 2: Gulf Pharmaceutical Industries, Julphar, United Arab Emirates

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A